An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects With Mesothelin-expressing Predominantly Epithelial Mesothelioma or Nonsquamous Non-small-cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Anetumab ravtansine (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Bayer
- 18 Sep 2017 Planned End Date changed from 6 Jul 2018 to 28 Mar 2019.
- 18 Sep 2017 Planned primary completion date changed from 26 Mar 2018 to 28 Mar 2018.
- 12 Apr 2017 Planned End Date changed from 15 Aug 2018 to 6 Jul 2018.